Results 201 to 210 of about 182,065 (262)

The association between an individual's development of non-communicable diseases and their spouse's development of the same disease: the Longitudinal Survey of Middle-aged and Elderly Persons. [PDF]

Environ Health Prev Med
Ukai T, Tabuchi T, Iso H.
europepmc   +1 more source

Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta-Analysis of Randomised Controlled Trials. [PDF]

Endocrinol Diabetes Metab
Basit J, Ahmed M, Singh P, Ahsan A, Zulfiqar E, Iqbal J, Fatima M, Upreti P, Hamza M, Alraies MC.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tendon Pathology in Hypercholesterolemia and Familial Hypercholesterolemia

Current Rheumatology Reports, 2017
Hypercholesterolemia (HC), or high cholesterol, is usually caused by diet, other health conditions, or inherited diseases, such as familial hypercholesterolemia (FHC). Studies have shown patients with hypercholesterolemia are more prone to tendon injury and impaired healing.
Brittany L. Taylor, Adnan N. Cheema, Louis J. Soslowsky   +2 more
openaire   +3 more sources

Psyllium in Hypercholesterolemia

Annals of Pharmacotherapy, 1995
In summary, within a controlled study situation, psyllium seems to be effective in lowering total and LDL cholesterol by 4-8% and 6-13%, respectively. Compared with conventional antilipidemic agents such as lovastatin, which lowers total cholesterol 30%, LDL cholesterol 40%, and triglycerides 20%, the effect of psyllium on lipids is minimal, and its ...
Donna J. Schroeder, Elaine K Chan
openaire   +2 more sources

Vitamin A in Hypercholesterolemia

The American Journal of the Medical Sciences, 1992
This study evaluated the relationship between plasma vitamin A and cholesterol in 48 patients with hypercholesterolemia studied before and after treatment with a cholesterol-lowering diet, with or without lipid-lowering medication. Plasma vitamin A levels were higher in hypercholesterolemic subjects than in healthy controls (2.58 +/- 0.15 vs.
Terrence T. Kuske, S B Leonard, Diane K. Smith, Elaine B. Feldman, Daniel S. Feldman, Jane M. Greene   +5 more
openaire   +3 more sources

Lovastatin for Hypercholesterolemia

Drug Intelligence & Clinical Pharmacy, 1988
Lovastatin is the first 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor approved for the treatment of primary hypercholesterolemia. It is indicated as adjunctive therapy to dietary control and should be initiated at 20 mg/d in the evening.
Karen C. Uvodich, Frederick P. Zeller
openaire   +3 more sources